Roughly 125 million people worldwide live with psoriasis, based on a global prevalence rate of about 4.4%. That figure comes from a 2023 survey spanning 20 countries across five continents, covering more than half the world’s population. In the United States alone, an estimated 7.5 million adults are affected.
Global Prevalence at a Glance
A large international study published in Acta Dermato-Venereologica surveyed people aged 16 and older across 20 countries between January and April 2023 and found psoriasis affects 4.4% of the global population. That’s a higher number than many older estimates suggested, partly because previous studies relied on physician-diagnosed cases and missed people who never sought treatment or received a formal diagnosis.
Prevalence varies significantly by region. Countries at higher latitudes, particularly in Northern Europe and North America, consistently report higher rates. Warmer, equatorial regions tend to have lower rates, though researchers debate whether this reflects true biological differences, varying levels of healthcare access, or differences in how populations report skin conditions.
How Common Psoriasis Is in the United States
Psoriasis is one of the most common autoimmune conditions in the U.S. It is significantly more prevalent among non-Hispanic white adults than other racial and ethnic groups, though it occurs across all populations. This disparity likely reflects a combination of genetic susceptibility and historical underdiagnosis in Black and Hispanic communities, where psoriasis can look different on darker skin tones and may be misidentified.
The condition carries a substantial financial burden. Average annual medical costs for a person with psoriasis reached $2,730 in 2020, while pharmacy costs climbed to $17,675 per year. That pharmacy figure reflects the high price of biologic therapies, which have become a mainstay of treatment for moderate to severe cases. Total direct medical and pharmacy spending for psoriasis in the U.S. hit $1.35 billion in 2020, and costs have risen steadily since 2016.
Who Gets Psoriasis
Psoriasis affects men and women at roughly equal rates. However, men typically develop more severe forms of the disease, which leads to differences in treatment intensity and clinical outcomes. Women are more likely to have milder presentations, though exceptions are common in both directions.
The condition can appear at any age, but onset follows two general peaks. The first and more common peak occurs between the late teens and mid-30s. A second, smaller peak appears between the 50s and 60s. Early-onset psoriasis tends to run more strongly in families and is often more persistent over a lifetime. Psoriasis in children is less common but not rare, and it can look different than in adults, sometimes appearing first on the scalp or in skin folds.
Severity Breakdown
Not everyone with psoriasis deals with the same level of disease. Severity is typically measured by how much skin is affected: less than 3% of the body surface is considered mild, 3% to 10% is moderate, and more than 10% is severe. For reference, your palm (including fingers) represents roughly 1% of your body surface area.
About three-quarters of people with psoriasis have mild disease, meaning their plaques are limited to small patches on the elbows, knees, scalp, or lower back. Nearly one-quarter have moderate to severe cases, which can cover large areas of the body and significantly affect quality of life, sleep, and mental health. Even mild psoriasis, though, can be disruptive depending on its location. Plaques on the hands, feet, face, or genitals can have an outsized impact on daily functioning regardless of total area.
The Psoriatic Arthritis Connection
Psoriasis isn’t limited to the skin. Globally, about 18% of people with psoriasis also develop psoriatic arthritis, a condition where the same overactive immune response attacks the joints. That average masks wide regional variation: in North America, the overlap is closer to 27%, while in Australasia it’s around 8%.
Adults are far more likely to develop this joint involvement than children, with rates of roughly 24% versus 9%. Women are slightly more likely than men to be affected (19% versus 16%). Psoriatic arthritis can appear years or even decades after skin symptoms begin, which is why rheumatologists recommend that anyone with psoriasis pay attention to new joint pain, stiffness, or swelling, particularly in the fingers, toes, and lower back. Early treatment can prevent permanent joint damage.
Why the Numbers Keep Changing
If you’ve seen different prevalence figures across different sources, that’s normal. Older studies often cited rates of 2% to 3%, while newer data pushes the number closer to 4% or higher. Several factors explain this shift. Self-reported surveys capture people who have psoriasis but haven’t seen a dermatologist, which medical-record studies miss. Greater public awareness means more people now recognize their symptoms as psoriasis rather than dismissing them as dry skin or eczema. And diagnostic criteria have broadened over time to include milder presentations that might once have gone unrecorded.
What’s clear across all estimates is that psoriasis is far more common than most people assume. It ranks among the most prevalent immune-mediated diseases on the planet, affecting more people than many better-known conditions like lupus or multiple sclerosis combined.